- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04204161
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
February 3, 2021 updated by: Shenzhen BinDeBio Ltd.
A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma
This is a single arm, open-label, uni-center, phase I study .
In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety and efficacy of treatment.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yang Zhonghua
- Phone Number: 18938688105
- Email: zh.yang@bindebio.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital Central South University
-
Contact:
- Yang Minghua, PhD
- Phone Number: 13973135843
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Male and female subjects with CD19+/CD22+ B cell malignancies who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled.
- no available curative treatment options (such as autologous or allogeneic SCT)
- If patients had receive immunotherapy, they should reach requirments:tumor recurrency or the number of B cells recovered.
- Patients with recurrence after hematopoietic stem cell transplantation need additional satisfaction: 1) no GvHD and not require immunosuppression;2) stem cell transplantation was completed for at least 4 months, and at least 6 months before the CART reinfusion;
- Patients must be willing to sign an informed consent.
- Age:≤18 years.
- survival>12 weeks
- Flow cytometry or IHC showed positive expression of CD19/ CD22 in tumor cells within two months.
- Routine blood test:hemoglobin>=90 g/L; platelet>=50×10^9/L.
- Liver function: ALT and AST≤2.5 (ULN) times the upper limits of normal (if abnormal liver function is mainly caused by tumor infiltration, it can ≤5 ULN), bilirubin <2.0 mg/dl.
- Renal function:BUN: 9-20mg / dl; serum creatinine<= 1.5 times upper limits of normal; endogenous creatinine clearance rate>=50 ml/min
- Negative serum antibody for EBV, CMV, HIV , syphilis, HBVa nd HCV.
- Cardiac function: stable hemodynamic and left ventricular ejection fraction (LVEF)>=55%.
- ECOG score ≤2。
- Adequate venous access for apheresis, and no other contraindications for leukapheresis
Exclusion Criteria:
- ECOG >= 3.
- Patients with history of T cell tumors .
- organ failure:heart failure Ⅲ and Ⅳ;The liver reached grade C of child-turcotte .Renal failure and uremia;Respiratory failure;People with impaired consciousness.
- Acute or chronic GVHD after allogeneic hematopoiesis. Hormone or immunosuppressant was used within 30 days.
- steroid hormoneswere used before and after blood collection and infusion.
- HIV infection or active hepatitis B or hepatitis C infection.
- Uncontrolled active infection.
- Enrolled to other clinical study in the last 4 weeks.
- Subjects with systemic auto-immune disease or immunodeficiency.
- Allergic to cytokines.
- Definite neuropathic or psychotic patients, including authors of dementia or seizures, history of psychotropic substance abuse and unable to quit, or other substantial lesions that may increase central neurotoxicity.
- Patients with malignant tumors of the central nervous system.
- Lung, brain or intestinal tumor infiltrates.
- The second tumor was found.
- Allergic to cytokine antagonists.
- Other patients that researchers considered unsuitable for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CAR-T19/CAR-T22
CAR-T19/CAR-T22 (autologous T cells transduced with CD19 / 22 CAR-ζ/4-1BB vector) will be administered to children with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity.
|
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10^5/kg-2.5x10^8/kg .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0
Time Frame: 60 months
|
Safety evaluation
|
60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CAR-T cells testing
Time Frame: 60 months
|
The level of CAR-T cells will be tested regularly by Real-time Quantitative Polymerase Chain Reaction Detecting System(qPCR) or Flow cytometry to evaluate the proliferation in vivo and long-term survival.
|
60 months
|
Overall remission rate
Time Frame: 60 months
|
Overall remission rate consists of complete remission rate and partial remission rate of patients being treated with CAR-T19/CAR-T22
|
60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Yang Zhonghua, Shenzhen BinDeBio Tech Co.,Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 8, 2019
Primary Completion (ANTICIPATED)
October 30, 2021
Study Completion (ANTICIPATED)
October 8, 2024
Study Registration Dates
First Submitted
December 13, 2019
First Submitted That Met QC Criteria
December 17, 2019
First Posted (ACTUAL)
December 18, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 4, 2021
Last Update Submitted That Met QC Criteria
February 3, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019XY-BDB011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood
-
Shenzhen BinDeBio Ltd.Children's Hospital of Fudan UniversityActive, not recruitingRelapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, ChildhoodChina
-
Medical College of WisconsinUniversity of Wisconsin, Madison; AmgenRecruitingB-cell Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | B-Cell ALL, ChildhoodUnited States
-
Autolus LimitedCompletedCD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic LeukemiaUnited Kingdom
-
Shenzhen BinDeBio Ltd.The First Affiliated Hospital of Zhengzhou UniversityUnknownRefractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia | Relapsed/Refractory B-cell LymphomaChina
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on CAR-T19/CAR-T22
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRecruitingPlasma Cell Leukemia | Relapsed/Refractory Multiple MyelomaChina
-
Cellular Biomedicine Group Ltd.Chinese PLA General HospitalUnknownRelapsed or Refractory Acute Lymphoblastic LeukemiaChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingB-cell Non Hodgkin LymphomaChina
-
Cellular Biomedicine Group Ltd.The First Affiliated Hospital with Nanjing Medical UniversityCompletedRefractory Diffuse Large B-Cell LymphomaChina
-
Nexcella Inc.Not yet recruitingLight Chain (AL) AmyloidosisUnited States
-
Second Affiliated Hospital, School of Medicine,...RecruitingRelapsed and Refractory B-cell LymphomaChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingB-cell Non Hodgkin LymphomaChina
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...WithdrawnAcute Lymphoblastic Leukemia | Non-hodgkin LymphomaUnited States
-
Nanjing IASO Biotechnology Co., Ltd.Ruijin HospitalRecruitingPlasma Cell Leukemia | Relapsed/Refractory Multiple MyelomaChina